CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past few shares of mine. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire employment interview which I came away with an inadequate opinion of the company.

Irony of irony, my poor opinion of the business has grown steadily, although the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how as well as linked intellectual property from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) as well as the very first new drug application endorsement ($five million), and also royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it has this single remedy in addition to a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Might it all be smoke and mirrors? That’s a question I’ve been asking myself from the really beginning of the interest of mine in this particular organization. Judging by the multiples of a huge number of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or even some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Comments are Disabled